Adagene Inc
ADAG1.940USD
+0.020+1.04%
取引時間 （ET）15分遅れの株価
114.24M時価総額
--直近12ヶ月PER
詳細情報 Adagene Inc 企業名
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
企業情報
企業コードADAG
会社名Adagene Inc
上場日Feb 09, 2021
最高経営責任者「CEO」Dr. Peter (Peizhi) Luo, Ph.D.
従業員数138
証券種類Depository Receipt
決算期末Feb 09
本社所在地4F, Building C14, No. 218, Xinghu Street
都市SUZHOU
証券取引所NASDAQ Global Market Consolidated
国China
郵便番号- -
電話番号8651287773632
ウェブサイトhttps://www.adagene.com/
企業コードADAG
上場日Feb 09, 2021
最高経営責任者「CEO」Dr. Peter (Peizhi) Luo, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-3.45%
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Lefei Sun
Mr. Lefei Sun
Director
Director
--
--
Dr. Li Min, Ph.D.
Dr. Li Min, Ph.D.
Independent Director
Independent Director
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
Ms. Yuwen Liu
Ms. Yuwen Liu
Independent Director
Independent Director
--
--
Dr. Zheng Songmao
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-3.45%
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Lefei Sun
Mr. Lefei Sun
Director
Director
--
--
Dr. Li Min, Ph.D.
Dr. Li Min, Ph.D.
Independent Director
Independent Director
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
収益内訳
FY2024
FY2023
FY2022
FY2021
FY2020
データなし
地域別USD
会社名
収益
比率
China (Mainland)
103.20K
0.00%
事業別
地域別
データなし
株主
更新時刻: Fri, May 16
更新時刻: Fri, May 16
株主統計
種類
株主統計
株主統計
比率
WuXi AppTec Co, Ltd.
8.45%
General Atlantic LLC
8.12%
Olive Tree Capital
7.57%
HSG Holding Ltd.
2.85%
Luo (Peter)
2.77%
Other
70.23%
株主統計
株主統計
比率
WuXi AppTec Co, Ltd.
8.45%
General Atlantic LLC
8.12%
Olive Tree Capital
7.57%
HSG Holding Ltd.
2.85%
Luo (Peter)
2.77%
Other
70.23%
種類
株主統計
比率
Investment Advisor
17.67%
Private Equity
8.12%
Venture Capital
7.57%
Individual Investor
2.77%
Corporation
1.93%
Investment Advisor/Hedge Fund
0.02%
Other
61.91%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
32
17.95M
38.09%
-2.89M
2025Q1
34
22.22M
47.17%
+1.25M
2024Q4
30
19.43M
43.91%
+6.91M
2024Q3
29
16.58M
37.45%
+3.51M
2024Q2
30
13.07M
29.54%
-384.35K
2024Q1
31
14.15M
32.04%
+4.42M
2023Q4
27
7.53M
17.08%
-3.44M
2023Q3
33
8.73M
19.93%
-2.62M
2023Q2
35
8.75M
19.96%
-2.76M
2023Q1
46
8.82M
20.14%
-5.30M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
WuXi AppTec Co, Ltd.
3.98M
8.45%
--
--
Mar 31, 2025
General Atlantic LLC
3.83M
8.12%
--
--
Mar 31, 2025
Olive Tree Capital
3.57M
7.57%
--
--
Feb 28, 2025
HSG Holding Ltd.
1.34M
2.85%
--
--
Mar 31, 2025
Luo (Peter)
1.31M
2.77%
-46.66K
-3.45%
Feb 28, 2025
Impresa Management LLC
1.29M
2.74%
+1.29M
--
Feb 28, 2025
GP Healthcare Capital Co., Ltd.
910.00K
1.93%
+910.00K
--
Feb 28, 2025
Fidelity International
749.45K
1.59%
-2.53M
-77.11%
Mar 31, 2025
Fidelity Management & Research Company LLC
473.95K
1.01%
-707.69K
-59.89%
Jun 30, 2025
Mill Creek Capital Advisors, LLC
199.61K
0.42%
--
--
Mar 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
